Cost effectiveness and strategic planning (WHO-CHOICE)

WHO-CHOICE Interventions

Breast cancer


CODE DESCRIPTION COVERAGE
BRC-1 Stage I treatment: Lumpectomy with auxiliary dissection + radiotherapy to the breast + endocrine therapy where applicable 50%
BRC-2 Stage II treatment: Lumpectomy with auxiliary dissection + radiotherapy to the breast + endocrine therapy where applicable 50%
BRC-3 Stage III treatment: Neo-adjuvant chemotherapy + mastectomy with auxiliary dissection + adjuvant chemotherapy + endocrine therapy where applicable 50%
BRC-4 Stage IV treatment: Systemic chemotherapy + endocrine therapy for eligible patients 50%
BRC-5 Treatment all stages 50%
BRC-6 Optimal program: treatment of all stages plus a breast awareness program and early case finding through biannual mammographic screening in women age 50–70 years. 50%
BRC-7 Stage I treatment: Lumpectomy with auxiliary dissection + radiotherapy to the breast + endocrine therapy where applicable 80%
BRC-8 Stage II treatment: Lumpectomy with auxiliary dissection + radiotherapy to the breast + endocrine therapy where applicable 80%
BRC-9 Stage III treatment: Neo-adjuvant chemotherapy + mastectomy with auxiliary dissection + adjuvant chemotherapy + endocrine therapy where applicable 80%
BRC-10 Stage IV treatment: Systemic chemotherapy + endocrine therapy for eligible patients 80%
BRC-11 Treatment all stages 80%
BRC-12 Optimal program: treatment of all stages plus a breast awareness program and early case finding through biannual mammographic screening in women age 50–70 years. 80%
BRC-13 Stage I treatment: Lumpectomy with auxiliary dissection + radiotherapy to the breast + endocrine therapy where applicable 95%
BRC-14 Stage II treatment: Lumpectomy with auxiliary dissection + radiotherapy to the breast + endocrine therapy where applicable 95%
BRC-15 Stage III treatment: Neo-adjuvant chemotherapy + mastectomy with auxiliary dissection + adjuvant chemotherapy + endocrine therapy where applicable 95%
BRC-16 Stage IV treatment: Systemic chemotherapy + endocrine therapy for eligible patients 95%
BRC-17 Treatment all stages 95%
BRC-18 Optimal program: treatment of all stages plus a breast awareness program and early case finding through biannual mammographic screening in women age 50–70 years. 95%
Share